Lupin Unit Signs €75 Million YUVEZZI Licensing Deal, Expands Eye-Care Business Across Europe
Mumbai: Lupin's subsidiary VISUfarma has signed an exclusive licensing agreement with US-based Visus Therapeutics to commercialise the eye treatment YUVEZZI across European markets. The agreement covers the European Union, United Kingdom, Switzerland, Norway and Iceland. VISUfarma will handle regulatory work, marketing, promotion, distribution and sales in these territories. Deal worth up to €75…
We haven't written up this one. Free Press Journal has the full story — the link below goes straight to it.
